Dersimelagon for Erythropoietic protoporphyria and X-linked protoporphyria
The FDA is expected to decide on Dersimelagon for Erythropoietic protoporphyria and X-linked protoporphyria in By end of February 2027, under a NDA from LEO Pharma.
What is being decided
LEO Pharma has an NDA under FDA review for Dersimelagon in Erythropoietic protoporphyria and X-linked protoporphyria. Once-daily oral MC1R agonist under priority review; would be the first oral treatment for these light-sensitivity disorders. LEO Pharma has disclosed only that the action date falls by the end of February 2027.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Frequently asked questions
When will the FDA decide on Dersimelagon?
LEO Pharma has disclosed a decision window of By end of February 2027 for Dersimelagon in Erythropoietic protoporphyria and X-linked protoporphyria, without an exact date.
What is Dersimelagon being reviewed for?
LEO Pharma submitted a NDA for Dersimelagon in Erythropoietic protoporphyria and X-linked protoporphyria. Once-daily oral MC1R agonist under priority review; would be the first oral treatment for these light-sensitivity disorders. LEO Pharma has disclosed only that the action date falls by the end of February 2027.
What happens after the Dersimelagon decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from LEO Pharma announcement. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.